All In Biotech

Drug Trial Radar · NCT07146191

RE104 Radiolabeled Mass Balance (hAME) Study

A Phase 1, Open-label, Single Period Study to Evaluate the Absorption, Metabolism, and Excretion of a Single Microdose of [14C]-RE104 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Aug 19, 2025

Primary completion

Oct 2, 2025

Study completion Oct 2, 2025

Sponsor

Lead sponsor
Reunion Neuroscience IncIndustry
Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.

Conditions

  • Healthy Participant Study

Interventions

  • 2-[14C]-RE104 for InjectionDrug

    Single, subcutaneous dose of 2-\[14C\]-RE104 for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total excreted radioactivity (Ae)Time frame: Through 168 hours postdose
  2. Cumulative recovery of total excreted radioactivity (CUM Ae)Time frame: Through 168 hours postdose
  3. Area under the concentration-time curve (AUC) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
  4. Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
  5. Time to reach Cmax (Tmax) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
  6. Terminal half-life (t1/2) of RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
  7. Apparent terminal elimination half-life (λz) for RE104 and 4-OH-DiPTTime frame: Through 168 hours postdose
  8. Mean residence time (MRT)Time frame: Through 168 hours postdose
  9. Apparent total body clearance (CL/F) for RE104Time frame: Through 168 hours postdose
  10. Apparent volume of distribution during the terminal phase (Vz/F) for RE104Time frame: Through 168 hours postdose
  11. Total metabolite profiling with description of relevant PK parameters and structural identification of major metabolites present in all matricesTime frame: Through 168 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Inc.

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.